{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:39:03Z","timestamp":1789915143560,"version":"4.0.1"},"publisher-location":"Chichester, UK","reference-count":29,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd010885.pub2","type":"reference-entry","created":{"date-parts":[[2014,6,26]],"date-time":"2014-06-26T14:29:45Z","timestamp":1403792985000},"source":"Crossref","is-referenced-by-count":7,"title":["Different infusion durations for preventing platinum-induced hearing loss in children with cancer"],"prefix":"10.1002","author":[{"given":"Jorrit W","family":"van As","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira C","family":"van Dalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,6,26]]},"reference":[{"issue":"12","key":"10.1002\/14651858.CD010885.pub2-BIB1|cit1","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1200\/JCO.1997.15.12.3433","article-title":"NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatric Oncology","volume":"15","author":"Coze","year":"1997","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD010885.pub2-BIB2|cit2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/pbc.20379","article-title":"Long-term renal and hearing toxicity of carboplatin in infants treated for localized and unresectable neuroblastoma: results of the SFOP NBL90 study","volume":"45","author":"Bergeron","year":"2005","journal-title":"Pediatric Blood & Cancer"},{"issue":"2","key":"10.1002\/14651858.CD010885.pub2-BIB3|cit3","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/pbc.20673","article-title":"Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters","volume":"47","author":"Lanvers-Kaminsky","year":"2006","journal-title":"Pediatric Blood & Cancer"},{"issue":"10","key":"10.1002\/14651858.CD010885.pub2-BIB4|cit4","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/01.mph.0000141348.62532.73","article-title":"Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss","volume":"26","author":"Bertolini","year":"2004","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"key":"10.1002\/14651858.CD010885.pub2-BIB5|cit5","series-title":"Medical and Pediatric Oncology","first-page":"329 (abstract 1","article-title":"Ototoxicity in children treated with cis-platinum (CDDP) for germ cell (GCT) and other tumours","author":"Brock","year":"1987"},{"issue":"4","key":"10.1002\/14651858.CD010885.pub2-BIB6|cit6","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/mpo.2950190415","article-title":"Cisplatin ototoxicity in children: a practical grading system","volume":"19","author":"Brock","year":"1991","journal-title":"Medical and Pediatric Oncology"},{"issue":"2","key":"10.1002\/14651858.CD010885.pub2-BIB7|cit7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/MPH.0b013e31815d1d83","article-title":"Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens","volume":"30","author":"Dean","year":"2008","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"key":"10.1002\/14651858.CD010885.pub2-BIB8|cit8","unstructured":"Eloxatin Summary of Product Characteristics www.sanofi-aventis.co.uk\/products\/Eloxatin_SPC.pdf"},{"issue":"1","key":"10.1002\/14651858.CD010885.pub2-BIB9|cit9","doi-asserted-by":"crossref","first-page":"744","DOI":"10.7326\/0003-4819-91-5-744","article-title":"Furosemide-induced ototoxicity","volume":"91","author":"Gallagher","year":"1979","journal-title":"Annals of Internal Medicine"},{"issue":"9209","key":"10.1002\/14651858.CD010885.pub2-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(00)02044-4","article-title":"Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer","volume":"355","author":"Gietema","year":"2000","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD010885.pub2-BIB11|cit11","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1542\/pir.25-7-224","article-title":"Pediatric audiology: a review","volume":"25","author":"Gregg","year":"2004","journal-title":"Pediatrics in Review"},{"issue":"4","key":"10.1002\/14651858.CD010885.pub2-BIB12|cit12","doi-asserted-by":"crossref","first-page":"e938","DOI":"10.1542\/peds.2009-1597","article-title":"Auditory late effects of childhood cancer therapy: a report from the Children's Oncology Group","volume":"125","author":"Grewal","year":"2010","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD010885.pub2-BIB13|cit13","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010885.pub2-BIB14|cit14","first-page":"123","article-title":"Late effects of cancer treatment and current protective measures","volume-title":"Cancer in Children","author":"Jenney","year":"2005"},{"issue":"34","key":"10.1002\/14651858.CD010885.pub2-BIB15|cit15","doi-asserted-by":"crossref","first-page":"8588","DOI":"10.1200\/JCO.2004.00.5355","article-title":"Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development","volume":"23","author":"Knight","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010885.pub2-BIB16|cit16","unstructured":"Kremer LCM van Dalen EC Moher D Caron HN Cochrane Childhood Cancer Group About The Cochrane Collaboration 2008, Issue 3. Art. No.:Cochrane Review Groups (CRGs)"},{"issue":"8","key":"10.1002\/14651858.CD010885.pub2-BIB17|cit17","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.tips.2013.05.006","article-title":"Understanding platinum-induced ototoxicity","volume":"34","author":"Langer","year":"2013","journal-title":"Trends in Pharmacological Sciences"},{"issue":"10","key":"10.1002\/14651858.CD010885.pub2-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1200\/JCO.2011.39.4254","article-title":"A cautionary tale: dosing chemotherapy in infants with retinoblastoma","volume":"30","author":"Leahey","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"16","key":"10.1002\/14651858.CD010885.pub2-BIB19|cit19","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1016\/j.ejca.2003.08.009","article-title":"Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose","volume":"40","author":"Li","year":"2004","journal-title":"European Journal of Cancer"},{"issue":"2","key":"10.1002\/14651858.CD010885.pub2-BIB20|cit20","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0022-3476(83)80551-4","article-title":"Hearing loss in children receiving cisplatin chemotherapy","volume":"102","author":"McHaney","year":"1983","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD010885.pub2-BIB21|cit21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/b109924_13","article-title":"Auditory late effects of chemotherapy","volume":"150","author":"Meyer","year":"2009","journal-title":"Cancer Treatment and Research"},{"issue":"10","key":"10.1002\/14651858.CD010885.pub2-BIB22|cit22","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1200\/JCO.2011.36.9744","article-title":"Carboplatin-associated ototoxicity in children with retinoblastoma","volume":"30","author":"Qaddoumi","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD010885.pub2-BIB23|cit23","first-page":"19","article-title":"Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration","volume":"66","author":"Reddel","year":"1982","journal-title":"Cancer Treatment Reports"},{"issue":"12","key":"10.1002\/14651858.CD010885.pub2-BIB24|cit24","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/ng.478","article-title":"Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy","volume":"41","author":"Ross","year":"2009","journal-title":"Nature Genetics"},{"issue":"6","key":"10.1002\/14651858.CD010885.pub2-BIB25|cit25","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1200\/JCO.1989.7.6.754","article-title":"Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation","volume":"7","author":"Schell","year":"1989","journal-title":"Journal of Clinical Oncology"},{"issue":"16","key":"10.1002\/14651858.CD010885.pub2-BIB26|cit26","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/j.ejca.2004.08.002","article-title":"Best practice in assessing ototoxicity in children with cancer","volume":"40","author":"Skinner","year":"2004","journal-title":"European Journal of Cancer"},{"issue":"5","key":"10.1002\/14651858.CD010885.pub2-BIB27|cit27","article-title":"Medical interventions for the prevention of platinum-induced hearing loss in children with cancer","author":"As","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD010885.pub2-BIB28|cit28","first-page":"2205","article-title":"Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy","volume":"7","author":"Veal","year":"2001","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD010885.pub2-BIB29|cit29","unstructured":"World Health Organization WHO Handbook for Reporting Results of Cancer Treatment WHO offset publication no. 48. Geneva, Switzerland 1979"}],"updated-by":[{"DOI":"10.1002\/14651858.cd010885.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,8,8]],"date-time":"2016-08-08T00:00:00Z","timestamp":1470614400000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD010885.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T22:49:40Z","timestamp":1628549380000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD010885.pub2"}},"subtitle":[],"editor":[{"given":"Jorrit W","family":"van As","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,6,26]]},"references-count":29,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010885.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD010885.pub3","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2014,6,26]]}}}